Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT7 | O95251 | 16/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 16/20 | 0.43 |
| ▸ | KAT6B | Q8WYB5 | 13/20 | 0.43 |
| ▸ | KAT5 | Q92993 | 9/20 | 0.42 |
| ▸ | KAT8 | Q9H7Z6 | 9/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31516712 | 0.92 | KAT7 (0.44) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31172523 | 0.92 | KAT7 (0.47) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31172562 | 0.91 | KAT7 (0.43) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31516705 | 0.91 | KAT7 (0.45) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31172533 | 0.91 | KAT7 (0.47) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31172549 | 0.91 | KAT7 (0.49) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31516599 | 0.87 | KAT7 (0.42) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31172617 | 0.87 | KAT7 (0.41) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31172662 | 0.87 | KAT7 (0.41) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL31516839 | 0.87 | KAT7 (0.51) | KAT7KAT6AKAT6BKAT5KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | OLEMA PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | OLEMA PHARMACEUTICALS, INC. | 2025-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136553-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | KAT7 5/4885KAT6A 1/4885KAT6B 3/4885 |
| US-12428379-B2 | Acylsulfonamide KAT6A inhibitors | KAT6A, KAT2A, KAT6B | KAT7 5/4885KAT6A 1/4885KAT6B 3/4885 |
| US-20260015327-A1 | ACYLSULFONAMIDE KAT6A INHIBITORS | KAT6A, KAT2A, KAT6B | KAT7 4/4885KAT6A 1/4885KAT6B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.